Neurogene Inc
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disea… Read more
Neurogene Inc (NGNE) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.074x
Based on the latest financial reports, Neurogene Inc (NGNE) has a cash flow conversion efficiency ratio of -0.074x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.68 Million) by net assets ($265.54 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Neurogene Inc - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Neurogene Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Neurogene Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Neurogene Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shanghai Sanmao Enterprise Group Co Ltd B
SHG:900922
|
0.100x |
|
ANGEL OAK MTG DL-01
F:57V
|
N/A |
|
J.Jill Inc
NYSE:JILL
|
0.148x |
|
Tupy S.A
SA:TUPY3
|
0.101x |
|
Ever Fortune.AI Co. Ltd.
TWO:6841
|
0.013x |
|
CanAlaska Uranium Ltd
OTCQX:CVVUF
|
-0.153x |
|
TNG Limited
PINK:TNGZF
|
-0.025x |
|
Tonnellerie Francois Freres SA
PA:TFF
|
0.064x |
Annual Cash Flow Conversion Efficiency for Neurogene Inc (2011–2024)
The table below shows the annual cash flow conversion efficiency of Neurogene Inc from 2011 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $310.38 Million | $-70.60 Million | -0.227x | +17.71% |
| 2023-12-31 | $186.02 Million | $-51.42 Million | -0.276x | +48.39% |
| 2022-12-31 | $98.63 Million | $-52.82 Million | -0.536x | -206.05% |
| 2021-12-31 | $-91.88 Million | $-46.40 Million | 0.505x | +492.96% |
| 2020-12-31 | $191.22 Million | $-24.57 Million | -0.129x | -18.29% |
| 2019-12-31 | $141.69 Million | $-15.39 Million | -0.109x | +75.00% |
| 2018-12-31 | $72.67 Million | $-31.58 Million | -0.435x | +3.91% |
| 2017-12-31 | $98.89 Million | $-44.72 Million | -0.452x | -116.43% |
| 2016-12-31 | $144.66 Million | $-30.23 Million | -0.209x | -11.77% |
| 2015-12-31 | $108.42 Million | $-20.27 Million | -0.187x | +62.05% |
| 2014-12-31 | $36.15 Million | $-17.81 Million | -0.493x | -218.24% |
| 2013-12-31 | $51.28 Million | $-7.94 Million | -0.155x | +98.13% |
| 2012-12-31 | $874.03K | $-7.23 Million | -8.275x | -625.11% |
| 2011-12-31 | $8.59 Million | $-9.80 Million | -1.141x | -- |